REPRICING OF WARRANTS

Briacell to lower warrant exercise price to 14 cents

2017-10-03 18:09 ET - News Release

Ms. Farrah Dean reports
BRIACELL ANNOUNCES REPRICING OF WARRANTS
Briacell Therapeutics Corp. is applying to the TSX Venture Exchange for approval to amend the terms of an aggregate of 1,562,500 common share purchase warrants issued pursuant to a non-brokered private placement that closed on May 3, 2016.

The warrants are exercisable into common shares in the capital of the company at an exercise price of 35 cents per common share and are set to expire on April 28, 2019. Subject to exchange approval and the consent of all warrantholders, Briacell will amend the warrants by reducing the exercise price of the warrants from 35 cents to 14 cents, consistent with the current trading value of Briacell's shares.
In accordance with exchange requirements, the terms of each warrant are to be amended to include an accelerated expiry clause, such that the exercise period of the warrants will be reduced to 30 days if, for any 10 consecutive trading days during the unexpired term of the warrants, the closing price of the company's shares is 17.5 cents or more. The proposed warrant amendment is subject to exchange approval.

About Briacell Therapeutics Corp.
Briacell is an immuno-oncology-focused biotechnology company developing a targeted and safe approach to the management of cancer. Briacell's mission is to serve late-stage cancer patients with no available treatment options.